Automated DR grading with high sensitivity

EyeArt analyzes retinal images using deep learning algorithms trained on millions of scans. The system classifies images as 'referable' or 'non-referable' diabetic retinopathy within seconds, with sensitivity exceeding 90% for referable cases in published studies.

Business outcome: Reduces reliance on specialist graders and accelerates screening workflows.

Works with existing retinal cameras

The platform connects with most FDA-cleared fundus cameras, including models from Topcon, Canon, and Zeiss. No proprietary hardware is required, which lowers upfront investment for clinics already equipped with retinal imaging devices.

Business outcome: Eliminates capital expenditure on new imaging equipment for most practices.

Real-time results at point of care

EyeArt delivers analysis results immediately after image capture, allowing clinicians to discuss findings with patients during the same visit. This eliminates follow-up calls and reduces no-show rates for specialist referrals.

Business outcome: Improves patient compliance and reduces administrative overhead for referral management.

Structured reports for EHR integration

The system generates standardized reports compatible with major electronic health record platforms. Reports include image quality assessment, DR severity grading, and referral recommendations in a format suitable for clinical documentation.

Business outcome: Streamlines documentation and supports quality reporting for value-based care programs.

FDA-cleared with published clinical data

EyeArt has received FDA clearance for autonomous DR screening, supported by multiple clinical studies published in peer-reviewed journals. This regulatory standing is critical for liability-conscious healthcare organizations.

Business outcome: Provides legal and clinical confidence for non-ophthalmologist screening programs.

Cloud-based or on-premise deployment

Clinics can choose between cloud-based analysis for low upfront cost or on-premise deployment for facilities with strict data residency requirements. Both options support high-volume screening environments.

Business outcome: Flexible deployment matches IT infrastructure and data governance policies.

• High clinical accuracyPublished studies show sensitivity above 90% for referable diabetic retinopathy, meeting regulatory standards for autonomous screening.
• Regulatory clearanceFDA-cleared as a Class II medical device, providing legal protection for clinics using AI-driven screening without specialist oversight.
• Hardware agnosticWorks with most major retinal camera brands, avoiding vendor lock-in and additional capital costs.
• Immediate resultsAnalysis completes in seconds, enabling same-visit counseling and reducing the administrative burden of follow-up appointments.

• DR-specific onlyThe system does not screen for other eye diseases — patients still need comprehensive exams for glaucoma, cataracts, or macular degeneration.
• Image quality dependencyPoor-quality retinal images (blur, shadows, artifacts) can lead to ungradable results, requiring retakes or manual review.
• No public pricingCost transparency is limited — clinics must engage with sales to understand pricing, which slows procurement cycles.
• Professional RealityEyeArt is a screening tool, not a diagnostic device — positive results require confirmation by an eye-care specialist before treatment decisions.

Primary care annual diabetic exams

A 10-physician primary care group uses EyeArt to screen all diabetic patients during routine visits. The system flags 8% of patients as needing referral, reducing undiagnosed DR by 60% in the first year.

Endocrinology clinic workflow

An endocrinology practice integrates EyeArt into diabetes management visits. Patients receive retinal screening alongside HbA1c testing, creating a comprehensive diabetes care visit without additional appointments.

Community health center outreach

A rural health center deploys EyeArt with a portable retinal camera for mobile screening events. The AI enables on-site grading, eliminating the need for an ophthalmologist to travel to remote locations.

Health system population health

An accountable care organization uses EyeArt across 12 primary care sites to close diabetic retinopathy screening gaps. Within 18 months, the system increases screening rates from 45% to 78% in the covered population.

Contact Eyenuk to request a demo and discuss your clinic's volume, camera compatibility, and deployment preferences.

Complete the hardware compatibility check to confirm your existing retinal camera works with EyeArt's software.

Set up the integration with your EHR system for automated report generation and documentation.

Train clinical staff on image capture best practices and how to interpret EyeArt's output for patient discussions.